Special Issue

Current Advances in Chimeric Antigen Receptor Technology

Message from the Guest Editors

In recent years, there has been a significant advancement in the area of cellular immunotherapy, best exemplified by the remarkable success of the FDA-approved autologous chimeric antigen receptor (CAR) T cell therapy cells in patients with hematological malignancies. The application of CAR has been rapidly applied to other cells, such as natural killer (NK) cells, relieving drawbacks associated with the high cost and toxicity of CAR-T therapy. Currently, accelerated by synthetic biology, the design of CAR constructs is fast developing for specific recognition of cancerous cells and optimal antitumor response. These efforts will provide insight into the generation of safe and robust cytotoxic cells applicable to both blood and solid tumors as deliverable drugs. In this Special Issue, we welcome authors to submit original research articles and reviews, more precisely:

- Original research articles that provide preclinical and clinical evidence for potent CAR-mediated immunotherapies;
- Reviews on the advances of CAR technology on each generation, and obstacles to address in future.

Guest Editors

Dr. Seung-Hwan Lee

Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1N 6N5, Canada

Dr. Scott McComb

Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, ON, Canada

Deadline for manuscript submissions

closed (31 March 2022)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/58175

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)